Sensorion

Sensorion ROA

The Return on Assets (ROA) of Sensorion (ALSEN.PA) as of Oct 9, 2026 is -50.84 %. In the previous year, Return on Assets (ROA) was -29.09 % — a change of 74.75% (lower).

ROA

-50.84 %

YoY

74.75%

Last updated:

In 2025, Sensorion's return on assets (ROA) was -50.84 %, a 74.75% increase from the -29.09 % ROA in the previous year.

The Sensorion ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-130.45 EUR
Jan 1, 2019
-31.75 EUR
Jan 1, 2020
-13.23 EUR
Jan 1, 2021
-25.65 EUR
Jan 1, 2022
-59.62 EUR
Jan 1, 2023
-47.45 EUR
Jan 1, 2024
-29.09 EUR
Jan 1, 2025
-50.84 EUR
The Sensorion ROA history
YEARROAYoY
-50.84 %+74.75%
-29.09 %-38.68%
-47.45 %-20.42%
-59.62 %+132.44%
-25.65 %+93.89%
-13.23 %-58.34%
-31.75 %-75.66%
-130.45 %+50.31%
-86.79 %+38.76%
-62.55 %+141.92%
-25.85 %-81.60%
-140.55 %—
Access this data via the Eulerpool API

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

ROA Details

Understanding Sensorion's Return on Assets (ROA)

Sensorion's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Sensorion's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Sensorion's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Sensorion’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Sensorion stock

Return on Assets (ROA) of Sensorion is -50.84 % in 2025.

Return on Assets (ROA) of Sensorion changed from -29.09 % to -50.84 %, representing a 74.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Sensorion since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Sensorion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Sensorion

All Key Metrics — Sensorion